Myeloma, Amyloidosis, & Dysprotenemia

David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.

By Barbara J. Toman • February 6, 2024

In this month's "Hot Topic," David Murray, M.D., Ph.D., reviews the role of urine testing for monoclonal gammopathies and discusses Mayo Clinic’s use of MASS-FIX to replace traditional immunofixation testing.

By MCL Education • May 22, 2023

The assay is now recommended for diagnosing and monitoring patients with monoclonal protein disorders and exclusively available through Mayo Clinic Laboratories– Rochester.

By Mayo Clinic Laboratories • March 16, 2021

The results are part of a comprehensive study of 16,175 cases performed at Mayo Clinic over an 11-year period.

By Suzanne Ferguson • September 10, 2020

Matt Millen, ex-pro NFL player, who played on four Super Bowl-winning teams underwent a nearly six-year medical journey in search for answers. Finally, he was diagnosed with amyloidosis using a new testing methodology at Mayo Clinic.

By Chris Bahnsen • March 10, 2020

The standard laboratory test to diagnose multiple myeloma dates back to the Eisenhower administration. Research at Mayo Clinic spearheaded by David Murray, M.D., Ph.D. (PATH ’10), and fueled by his experience as an industrial chemist has led to a new assay to screen and diagnose the disease.

By Mayo Clinic Laboratories • April 29, 2019

This "Specialty Testing" webinar will cover the development work, clinical applications, analytical validation, and implementation of a MALDI-TOF mass spectrometry method (MASS-FIX) for the detection of monoclonal immunoglobulins M-proteins within the Mayo Clinic Protein Immunology Laboratory.

By MCL Education • March 28, 2019

Like a thief in the night, multiple myeloma sneaks up on people. The incurable blood cancer almost always starts as a relatively benign condition—monoclonal gammopathy of undetermined significance, or MGUS—that has no symptoms and often goes undiagnosed.

By Barbara J. Toman • January 11, 2019

David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests.

By Alyssa Frank • November 28, 2018

Multiple myeloma is the second most common blood cancer, but most people haven’t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month—a time to focus attention on the fight against multiple myeloma.

By Barbara J. Toman • March 6, 2018